The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global wound care biologics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Wound care biologics refer to drugs extracted or semi-synthesized from natural sources which are used for controlling and healing infections. Wound healing is a complex process involving inflammation, accumulation of fibrous tissue, deposition of collagen, formation of epithelial cell layers and other disruptions. Biologic wound healing treatments possess the ability to restore the natural repair mechanism through active biological agents. For instance, plant-derived active biomolecules with antimicrobial, anti-inflammatory or antioxidant properties have proven efficacious in advancing the wound-healing process. Some of the recent technological advancements made in the field of wound healing include skin substitutes, bio-membranes, scaffolds, hydroconductive dressings and biologics.
Chronic skin wounds can be caused due to burns, skin cancers, infections, trauma or an underlying medical condition such as diabetes. With the growing prevalence of these ailments along with the expanding geriatric population, there has been a rise in the demand for treatments that can accelerate wound healing and facilitate a speedy recovery. Along with this, several initiatives have been undertaken by governments across the globe to create awareness about the benefits of wound care biologics among patients. Apart from this, manufacturers are also developing next-generation, cost-effective and high-quality biologics to make them more accessible. Moreover, many research and healthcare centers are entering into partnerships to modernize wound care treatments and develop innovative drugs for healing wounds. For example, researchers are focusing on integrating antimicrobial compounds into the wound dressing itself. These materials combine traditional wound dressings such as hydrogels or foams with antimicrobial compounds such as betaine, silver, chitin, or polyhexamethylene biguanide.
IMARC Group provides an analysis of the key trends in each sub-segment of the global wound care biologics market, along with forecasts at the global and regional level from 2021-2026. Our report has categorized the market based on product, wound type, application and end-user.
Breakup by Product:
Breakup by Wound Type:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Smith & Nephew, Mölnlycke Health Care, Integra lifesciences, Osiris Therapeutics, Avita Medical, ConvaTec Group, Cytori Therapeutics, Mylan, Johnson & Johnson, Leap Therapeutics, Nuo Therapeutics, Mallinckrodt, Wright Medical, Mimedx Group, Solsys Medical, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Wound Type, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Smith & Nephew, Mölnlycke Health Care, Integra lifesciences, Osiris Therapeutics, Avita Medical, ConvaTec Group, Cytori Therapeutics, Mylan, Johnson & Johnson, Leap Therapeutics, Nuo Therapeutics, Mallinckrodt, Wright Medical, Mimedx Group and Solsys Medical|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at